
Sanofi
SNY
Updated: 23/09/2026, 18:15:14
Sanofi operates as a leading global pharmaceutical enterprise, dedicated to the research, development, production, and distribution of a wide array of therapeutic solutions across the United States, Europe, and numerous international markets. The company strategically organizes its operations into three core divisions: Pharmaceuticals, Vaccines, and Consumer Healthcare. Within its Pharmaceutical segment, Sanofi delivers specialized therapies, including innovative human monoclonal antibodies, addressing complex conditions like multiple sclerosis, various neurological disorders, immunology and inflammatory diseases, oncology, rare diseases, and rare blood disorders. This segment also encompasses treatments for diabetes, cardiovascular health, and established prescription medications. Its Vaccine portfolio is extensive, offering essential immunizations such as pediatric vaccines for poliomyelitis, pertussis, and Hib, alongside influenza shots, adult boosters, meningitis vaccines, and solutions for travel and endemic diseases. The Consumer Healthcare division provides a broad spectrum of over-the-counter products, including remedies for allergies, coughs and colds, pain management, liver support, physical and mental wellness, probiotics, digestive health aids, and nutritional supplements. Additionally, it offers various personal care items like daily body lotions, anti-itch creams, moisturizing and soothing lotions, body and foot creams, and specialized powders for eczema. Sanofi maintains a robust development pipeline, with numerous pharmaceutical products and vaccines currently in various stages of research. The company actively pursues strategic alliances, exemplified by its collaboration with GlaxoSmithKline on a recombinant Covid-19 vaccine, a research partnership with Stanford University School of Medicine focused on advancing immunology and inflammation understanding, and a collaboration and license option agreement with Prellis Biologics, Inc. Founded in 1973 and headquartered in Paris, France, the company was formerly known as Sanofi-Aventis before officially changing its name to Sanofi in May 2011.
No summaries found.
- Share price
- $41.62
- Market cap
- $99.93B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Belén Garijo López
- Employees
- 76,493
- IPO date
- 01/07/2002
- Beta
- 0.278
- Last dividend
- $0.00
- Day range
- $41.57 – $41.96
- 52-week range
- $40.89 – $52.68
- 1-day performance
- -2.10%
- 1-year performance
- 1.78%
- Current drawdown (1Y)
- -21.00%
- CIK
- 0001121404
- CUSIP
- 80105N105
- ISIN
- US80105N1054
- Created
- 07/12/2025, 14:19:26
- Last update
- 23/09/2026, 18:15:14
Track Sanofi with an AI analyst
See which prediction-market events move SNY, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
FDA approves Sanofi's drug for stage 3 type 1 diabetes in children
Reuters • STOCK • 12/06/2026, 19:19:26
Sanofi Ends Late-Stage Study on Neurology Drug Over Weak Results
Zacks Investment Research • STOCK • 10/06/2026, 12:07:09
Sanofi ends Phase 3 riliprubart trial after weak interim results
Reuters • STOCK • 10/06/2026, 04:38:42
Sanofi to Stop Late-Stage Study of Immune-Disorder Drug
WSJ • STOCK • 10/06/2026, 04:28:00
Press Release: Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
GlobeNewsWire • STOCK • 10/06/2026, 03:00:00
Sanofi Wins EU Nod for Subcutaneous Sarclisa in Multiple Myeloma
Zacks Investment Research • STOCK • 08/06/2026, 15:41:09
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi
Business Wire • STOCK • 05/06/2026, 09:00:00
Sanofi Stock Falls 6% in 3 Months: Should You Buy, Sell or Hold?
Zacks Investment Research • STOCK • 04/06/2026, 12:10:26
Press Release: Sanofi launches 2026 global employee stock purchase plan
GlobeNewsWire • STOCK • 04/06/2026, 06:07:00
FDA Grants Priority Review to SNY's Filing for Gaucher Disease Drug
Zacks Investment Research • STOCK • 29/05/2026, 13:01:14
Press Release: Sanofi's venglustat accepted for priority review in the US to treat type 3 Gaucher disease
GlobeNewsWire • STOCK • 28/05/2026, 03:00:00
Sanofi: Information concerning the total number of voting rights and shares - April 2026
GlobeNewsWire • STOCK • 19/05/2026, 14:37:00